Tanios Bekaii-Saab, MD, discusses how community oncologists can play an important role in the advancement of gastrointestinal (GI) cancers despite not having access to major trials.
Tanios Bekaii-Saab, MD, a professor of medicine at the Mayo Clinic, discusses how community oncologists can play an important role in the advancement of gastrointestinal (GI) cancers despite not having access to major trials.
Now, more than ever, there is a better understanding of alterations, mutations, amplifications, and fusions that are drivers, Bekaii-Saab says. Many studies now are looking at colorectal cancer to develop agents for the various subgroups.
Pembrolizumab/Trastuzumab/Chemo Enhances Survival in HER2+ Gastric Cancer
May 1st 2024The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.
Read More